Business Wire

Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases

Del

Boehringer Ingelheim and MiNA Therapeutics (“MiNA”), a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA’s small activating RNA (“saRNA”) therapeutics platform. The new partnership underscores Boehringer Ingelheim’s commitment to advancing innovative new treatment approaches and furthering its comprehensive clinical offerings in cardiometabolic diseases. It combines MiNA’s leading expertise in the development of saRNAs with Boehringer Ingelheim’s experience in bringing first-in-class breakthrough treatments to patients with cardiometabolic disease.

NASH is a major cause of liver fibrosis and cirrhosis and an area of high unmet medical need. It has an especially high prevalence among obese and diabetic patients and currently there are no treatments available. NASH is expected to become the most common cause of advanced liver disorders eventually necessitating liver transplantation in the coming decades.

saRNAs have been demonstrated to activate transcription of specific genes resulting in upregulation of proteins with therapeutic potential. In the new collaboration, Boehringer Ingelheim and MiNA aim to identify targets to restore metabolic functionality of hepatocytes and prevent fibrotic tissue formation in patients with NASH. It will enable Boehringer Ingelheim to rapidly design, profile and develop novel compounds, potentially also creating opportunities for combination with Boehringer Ingelheim’s other NASH-pipeline assets.

“This collaboration is a recognition of our platform and expertise in liver-based diseases as well as validation from an established pharmaceutical leader in what has been an exciting year for the company,” said Robert Habib, CEO of MiNA.

“This new collaboration is another sign of our ongoing commitment to patients with cardio-metabolic diseases, including NASH,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “It will combine MiNA’s pioneering work with saRNAs with our expertise in biopharmaceutical research and development,” added Wood.

Boehringer Ingelheim has a long history of excellence in the discovery and development of medicines for cardiometabolic disease patients. It has established a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute myocardial infarction, hypertension and cardio-renal risk reduction. The cardiometabolic diseases pipeline extends beyond type 2 diabetes and anticoagulation with a focus on innovative drugs for the treatment of the devastating consequences of diabetes as well as contributing factors like obesity.

Under the terms of the agreement, MiNA will receive an upfront payment and committed research funding as well as potential research, development and regulatory milestone payments totalling up to EUR 307 million. In addition, MiNA is entitled to up to double-digit royalties on sales of selected products resulting from the partnership. No further financial details have been disclosed.

In this agreement, MiNA was advised by Ferghana Partners and Taylor Wessing LLP.

Please click on the link below for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/collaboration-mina-develop-nash-treatments

Contact information

Contact for MiNA Therapeutics:
Dr. Stephanie May
MacDougall Biomedical Communications
P: +49 89 2424 3494 :: M: +49 175 571 1562
E-Mail: smay@macbiocom.com
or
Contacts for Boehringer Ingelheim:
Boehringer Ingelheim

Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim GmbH
P: +49 6132 77-90815 :: M: + 49 151 150 20 690
reinhard.malin@boehringer-ingelheim.com
or
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, Connecticut
P: +1 203 791-6672 :: M: +1 203-957 5114
linda.ruckel@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

FLIR Introduces Assisted Docking Technology and First Boat Manufacturer Partner22.1.2019 09:00Pressemelding

FLIR Systems, Inc. (NASDAQ: FLIR) today announced the Raymarine DockSense™ assisted docking system, the marine industry’s first intelligent object recognition and motion sensing assisted docking solution for recreational boating. DockSense system uses FLIR machine vision camera technology and video analytics to integrate intelligence gathered from surrounding imagery with the vessel’s propulsion and steering system to assist boat owners in tight quarter docking maneuvering. Additionally, FLIR announced that Prestige Yachts, a Groupe Beneteau brand, will become the first to demonstrate the technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190122005313/en/ Docking a boat can be a stressful experience, even for the most experienced captains. Often wind and tides make the task more difficult, and docking mishaps can become expensive repairs and safety hazards. The DockSense system is designed to augment a captain's boat

BIOCERES and UNION ACQUISITION CORP. announce Bioceres’ unaudited quarterly operating results for the period ended December 31, 201822.1.2019 08:52Pressemelding

Bioceres, a leading Latin American agricultural biotech company (the “Company”), and Union Acquisition Corp. (NYSE: LTN) (“UAC”), a special purpose acquisition company, today announced the Company’s unaudited operating results for the quarter ended December 31, 2018. The parties had previously announced the execution of a definitive share exchange agreement (the “Exchange Agreement”) pursuant to which the Company will contribute its agricultural solutions business in exchange for equity of UAC. The Company reported unaudited revenues of $62.6 million during the quarter ended December 31, 2018, which represents a 33% growth rate over the same period a year ago. The adjustments and the translation mechanism from the application of IAS 29 had a positive impact of $8.7 million during the quarter ended December 31, 2018. Additionally, the Company’s management team expects Gross Profit and EBITDA margin performance to exceed that of the same period a year ago. Members of UAC’s sponsor and, o

Tradeshift Announces Record Year and Exceptional Growth in Every Category Heading Into 201922.1.2019 08:00Pressemelding

Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the fourth quarter of 2018, marking the eleventh quarter in a row of successive growth and beating targets. Tradeshift’s fourth quarter growth stats announced today include: YoY new bookings grew 250 percent New total contract value grew by $59M in Q4 YoY revenue grew 178 percent (trailing 12 months) Gross Merchandise Volume (GMV) more than doubled, growing by 112 percent YoY Tradeshift Go experienced high growth with 12 deals signed in Q4 Signed App partner Transfermate, allowing Tradeshift customers to easily receive and make foreign currency payments Expanded Partner ecosystem with two additional BPO partners signed The company’s customer roster continued strong growth this quarter adding a record 49 new customers, including Charter Hall, HSBC, Econocom and more. “2018 was a record setting operational year for us,” said Christian Lanng, CEO and co-founder of Tradeshift. “It’s been so grati

Bridgestone Europe To Acquire TomTom Telematics For €910 Million Cash Consideration22.1.2019 06:58Pressemelding

Bridgestone Europe NV/SA (“Bridgestone”), a subsidiary of Bridgestone Corporation in EMEA, has entered into an agreement with TomTom to acquire its telematics business, for a cash consideration of €910 million. The transaction will bring together the world’s largest tyre and rubber company with the number one provider of digital fleet solutions in Europe, creating a leading data platform for connected vehicles. TomTom Telematics will accelerate Bridgestone on its journey to becoming a mobility solutions leader in the region, and the combination of both companies’ offerings will allow Bridgestone to cross-sell tyres and solutions to a larger customer base. Furthermore, the data access will enhance Bridgestone’s virtual tyre development and testing as well as connected tyre innovation benefiting all customers including OEMs. New social, economic and technological megatrends are pushing the pace of change in the automotive industry and the future of vehicles is connected, autonomous, shar

Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments22.1.2019 06:00Pressemelding

Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology. The collaboration brings together specialist expertise from Karolinska Institutet in early stage research, Rebiotix Inc. (acquired by Ferring in 2018), a late-stage clinical microbiome company, and Ferring’s therapeutic area and commercialisation capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005428/en/ The extension includes six reproductive health clinical studies of approximately 6,000 women and babies and four gastroenterology studies of approximately 3,000 adults and children, to further investigate the role of the microbiome in areas of high unmet need including recurrent pregnancy loss, preterm birth and inflammatory bowel disease. “The extension of this partnership presents a

GA Telesis Board Appoints Norman Liu as an Independent Director22.1.2019 06:00Pressemelding

GA Telesis, LLC, a leading global commercial aviation integrated services provider, announces that its Board of Directors will appoint Norman C.T. Liu as an Independent Board Member effective February 1, 2019. Norm brings over 35 years of experience in aviation financing, infrastructure investing and investment banking. He is the former Chairman, President and CEO of GE Capital Aviation Services (“GECAS"), a world leader in commercial aircraft leasing and financing. He retired from GE at the end of 2016 after 30 years of service and is currently a senior advisor to various companies in the infrastructure and aviation sectors. He was an Advanced Leadership Fellow at Harvard in 2017 and also serves as an Adjunct Professor at University College Dublin in Ireland. He received his bachelor’s degree from Yale University and his MBA from Harvard Business School. “We are pleased that Norm will be joining our Board to participate in the explosive growth of our franchise,” said Abdol Moabery, Pr